<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685997</url>
  </required_header>
  <id_info>
    <org_study_id>80-82310-98-08012</org_study_id>
    <nct_id>NCT00685997</nct_id>
  </id_info>
  <brief_title>Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas</brief_title>
  <official_title>Whole-body MR Imaging for Staging Malignant Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The malignant lymphomas, Hodgkin´s disease (HD) and non-Hodgkin´s lymphoma (NHL), comprise&#xD;
      approximately 5-6% of all malignancies in adults and account for 10% of childhood cancers.&#xD;
      Once the diagnosis has been established histologically, extent of disease (staging) and&#xD;
      response to therapy will be assessed by means of a computed tomography (CT) scan of the body.&#xD;
      The staging at presentation is important for determining prognosis and choice of treatment.&#xD;
      Unfortunately, CT is accompanied by a significant amount of radiation exposure which may&#xD;
      induce second cancers. This is especially important in childhood, because rapidly dividing&#xD;
      cells are more sensitive to radiation induced effects and children will have more years ahead&#xD;
      in which cancerous changes might occur. New magnetic resonance imaging (MRI) techniques offer&#xD;
      an alternative way for staging and follow-up of cancers, including the malignant lymphomas.&#xD;
      Whole-body MRI (WB-MRI) is a radiation-free method which allows imaging of the body with&#xD;
      excellent soft tissue contrast in a single examination.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      The aim of this study is to examine if WB-MRI can replace CT in staging of patients with a&#xD;
      malignant lymphoma.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      This will be a multicenter, prospective, diagnostic cohort study (timeschedule: 36 months).&#xD;
      135 eligible patients will undergo WB-MRI on top of the protocolar imaging routinely done.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients aged 8 years and older with a histological diagnosis of HD or NHL.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      The challenge of this study will be to show non-inferiority of WB-MRI compared to CT in&#xD;
      staging malignant lymphoma. Testing of this hypothesis will be one-sided and performed using&#xD;
      recently proposed techniques by Lui et al.&#xD;
&#xD;
      Radiation-related risk assessment:&#xD;
&#xD;
      A risk model will be used, based on the BEIR VII report, for modelling the late-term&#xD;
      mortality from radiation induced tumors after exposure to ionizing radiation.&#xD;
&#xD;
      Economic evaluation:&#xD;
&#xD;
      Actual costs (from a societal perspective) will be determined for the two diagnostic tests.&#xD;
      In case of clinical equivalence and similar costs or cost savings associated with MRI the&#xD;
      latter can be considered dominant, obviating further economic evaluation. Otherwise, through&#xD;
      modelling of expected long term health impact and associated outcomes such as quality of life&#xD;
      and costs the incremental cost effectiveness will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be the clinical stage according to WB-MRI findings and according to CT-findings. This clinical stage will be determined according to the Ann Arbor classification system.</measure>
    <time_frame>December 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome will be a (subjective) assessment of image quality and presence of artefacts, for both T1-weighted and T2-weighted MR images as well as CT.</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">135</enrollment>
  <condition>Malignant Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, aged 8 years and older, with newly diagnosed Hodgkin's disease or non-Hodgkin's&#xD;
        lymphoma, who will undergo computed tomography (CT) for staging&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female patients&#xD;
&#xD;
          -  age: 8 years and older&#xD;
&#xD;
          -  histologically proven Hodgkin's disease or non-Hodgkin's lymphoma&#xD;
&#xD;
          -  patients scheduled for a CT of the body for initial staging&#xD;
&#xD;
          -  participant's parents (participant &lt; 18 years) or the participant (participant &gt;18&#xD;
             years) must willingly give written informed consent prior to the start of the study&#xD;
&#xD;
          -  whole-body MRI has to be performed within 10 days before or after CT, and before&#xD;
             therapy has been started.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with a general contraindication for MRI (including cardiovascular pacemakers,&#xD;
             claustrophobia)&#xD;
&#xD;
          -  patients who have had a previous malignancy&#xD;
&#xD;
          -  patients who are pregnant or nursing&#xD;
&#xD;
          -  patients in whom therapy has already started after CT and before MRI could be&#xD;
             performed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rutger A. J. Nievelstein, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medical Center Amersfoort</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol. 2005 Sep;185(3):711-6.</citation>
    <PMID>16120924</PMID>
  </reference>
  <reference>
    <citation>Kellenberger CJ, Epelman M, Miller SF, Babyn PS. Fast STIR whole-body MR imaging in children. Radiographics. 2004 Sep-Oct;24(5):1317-30. Review.</citation>
    <PMID>15371611</PMID>
  </reference>
  <reference>
    <citation>Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, Ruehm SG, Barkhausen J. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004 Oct;233(1):139-48. Epub 2004 Aug 18.</citation>
    <PMID>15317952</PMID>
  </reference>
  <reference>
    <citation>Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF, Ruehm SG. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003 Dec 24;290(24):3199-206.</citation>
    <PMID>14693872</PMID>
  </reference>
  <reference>
    <citation>Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007 Nov 29;357(22):2277-84. Review.</citation>
    <PMID>18046031</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>July 2, 2013</last_update_submitted>
  <last_update_submitted_qc>July 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>R.A.J. Nievelstein</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Malignant lymphoma</keyword>
  <keyword>Hodgkin's disease</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>Imaging</keyword>
  <keyword>Whole-Body MRI</keyword>
  <keyword>CT</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

